The Virtual NP Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.5/10
Best for: seeing what it charges before you answer any medical questions
The Virtual NP's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
Not stated
Clinician visits
Not stated
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Two ways to pay: 99 dollars once, as you go, or 75 dollars per month for a membership carrying prescription access. Either way the drug is billed on its own, at a cost stated upfront. No compounded GLP-1 is sold. What gets written is branded and FDA-approved, made by Eli Lilly and Novo Nordisk: Zepbound (tirzepatide), Wegovy (semaglutide). HSA/FSA funds are taken and the clinic will help with prior authorization. Sandra Jordan, MSN, APRN, FNP-C founded and runs it, booking most patients inside 24 hours, with medication sent home.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to The Virtual NP
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
The Virtual NP at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Branded Zepbound, Branded Wegovy
- Starting price
- $75/mo
- Availability
- 7 states
- FDA status
- No FDA warning letter on record
How The Virtual NP scores
Six columns, each one computed from something The Virtual NP has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10The figures published here are not comparable monthly cash prices for the medication — an insured copay, a per-vial rate, a membership fee or a starting-dose teaser. Capped rather than scored against the register.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
7.5/10On the seller's own pages, a price is published before the questionnaire starts; a live video visit is required, which is slower but is the more careful intake.
Trust & Safety15%
8.5/10does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is high.
Accessibility10%
3.1/10Publishes coverage in 7 of 50 states.
Support10%
5.0/10States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on The Virtual NP
Last checked August 2026- Re-read the price on file across 2 dose or plan tiers
- Checked state coverage: 7 states
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
What signing up with The Virtual NP involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1The Virtual NP publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake requires a live video visit with a clinician, which is more than most of the register asks and slower to complete.
- 3The Virtual NP does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- No comparable monthly cash price for the medication is on record — either nothing is published, or what is published is a fee, an insured copay or a per-vial rate rather than a monthly cost.
- Coverage is published for 7 of 50 states.
The Virtual NP support, as documented
- Phone
- (214) 216-6320
- Hours
- Mon-Fri 7am-7pm, Sat 9am-5pm, Sun 11:30am-5pm
GLP-1 medications The Virtual NP offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Check the price yourself before you pay
Every figure here was read off The Virtual NP's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- No FDA warning letter matched this operator when we searched our enforcement register
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Against it
- Coverage is published for 7 states only, so this may not reach you
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
What The Virtual NP charges
The Virtual NP lists $75/month. That sits at the affordable end of what we track.
- Brand-name tirzepatide — $75/month
- Brand-name semaglutide — $75/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so The Virtual NP is genuinely under the middle rather than merely advertising that it is.
Boston Medical Group dispenses semaglutide and tirzepatide from $66/month, which makes it the honest comparison to run before committing here.
What The Virtual NP dispenses
The Virtual NP prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. These are FDA-approved brand-name products rather than compounded preparations, which is the more expensive route and the one where what is in the vial has been reviewed.
What we could verify
On the record: it operates in 7 states. We searched the federal warning-letter record for this operator and came back with nothing. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
Our read
The Virtual NP competes on price and does it without an obvious sacrifice elsewhere: $75/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
The Virtual NP's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay The Virtual NP
Starting at $75/month. Check today's price, then book the free consultation.
Where The Virtual NP is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
- If you want a human checking in, not just a prescription, consider Oak.
- If your state is outside the area this one covers, consider Direct Meds.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this The Virtual NP review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See The Virtual NP's current pricing
Plans start at $75/month. The free consultation is where you learn whether you qualify, and what it costs today.